Leipzig. BlackSwan Pharma GmbH, a developer of small molecule agents for the treatment of chronic lymphocytic leukaemia, announced today that the company will present its drug candidate CD-160130 at the poster session on new substances at the German CLL Study Group´s 22nd Work Meeting in Kiel, 25/26 September 2009.
